AP NEWS
Click to copy
Press release content from BusinessWire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from BusinessWire
Press release content from BusinessWire. The AP news staff was not involved in its creation.

Sensile Medical formed a strategic alliance with Sanofi and Verily to develop and commercialize a connected insulin patch pump

June 26, 2018

OLTEN, Switzerland--(BUSINESS WIRE)--Jun 26, 2018--With its long-standing commitment to addressing the needs of people living with diabetes, Sanofi announced today a new development and commercialization alliance at the American Diabetes Association (ADA) 78th Scientific Sessions in Orlando, Florida, U.S.

Sensile Medical, Sanofi and Verily (formerly Google Life Sciences) are collaborating on development and commercialization of a connected insulin patch pump.

The 3 parties develop and commercialize a new generation of “all-in-one” pre-filled insulin patch pump, primarily to serve people living with type 2 diabetes.

The alliance will leverage Sanofi’s expertise in patient-centered diabetes solutions and insulins, Sensile Medical’s leadership in developing micro-pump technologies for medical use, and Verily’s experience in micro-electronic integration and digital healthcare technology.

“ Our goal is to develop a new type of pump technology that is simple to use and appropriate for people with Type 2 diabetes, as well as by those with Type 1 diabetes who are the primary users of insulin pumps today,” said Derek Brandt, CEO of Sensile Medical.

About Sensile Medical

Sensile Medical Ltd. Is a globally leading Swiss medical technology company in the field of Large Volume Injectors. In close corporation with pharma and biotech companies, we develop devices for liquid drug delivery. The core of our system is the patented SenseCore technology. The micro pump is cost-efficient to produce and very accurate in dosage. Our aim is, to build bridges from drugs to patients. Therefore, our designs are characterized by modularity and flexibility to meet the patient’s needs in the best possible way. Sensile Medical employs about 120 employees at the headquarter in Olten. For more information, visit our website www.sensile-medical.com or our profile on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180626006139/en/

CONTACT: Sensile Medical AG

Sandra de Haan, Chief Business Officer

Sandra.dehaan@sensile-medical.com

+41 62 209 71 00

KEYWORD: EUROPE GERMANY SWITZERLAND

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MEDICAL DEVICES PHARMACEUTICAL DIABETES

SOURCE: Sensile Medical AG

Copyright Business Wire 2018.

PUB: 06/26/2018 10:56 AM/DISC: 06/26/2018 10:56 AM

http://www.businesswire.com/news/home/20180626006139/en

All contents © copyright 2019 The Associated Press. All rights reserved.